To Determine the Relationship Between Baseline Reversibility and the Efficacy of Indacaterol

• Status: Completed
• Trial end date: 2012-05-01

Summary

In this 5-months study, the response of patients to salbutamol at baseline will be compared with their response to treatment with indacaterol.

• Phase: Phase 4

Details

• Lead Sponsor: Novartis Pharmaceuticals